Estimating the Prevalence of GAstrocnemius Muscle REtraction in a Population Suffering From Plantar aPOneurositis and Describing the Effects of Lengthening

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorClinique Saint Charles

About this trial

The gastrocnemius muscles, which form the upper part of the calf, can suffer from retraction, a common but often under-diagnosed condition, which can be a risk factor for plantar fasciitis. Retraction can be treated medically, by stretching, or surgically, by lengthening the muscles. Gastrocnemius retraction is difficult to measure, but tests such as the Ankle Dorsiflexion Index (ADI) provide a more accurate assessment.

Knowing the prevalence of this retraction in patients suffering from plantar fasciitis would enable us to improve diagnostic criteria and better target treatments. Surgical lengthening of the gastrocnemius, particularly by tenotomy, is effective in cases of chronic plantar fasciitis, even without apparent muscle retraction.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient aged 70 or under

Patient suffering from unilateral plantar fasciitis that has progressed for more than 6 months and is recalcitrant to medical treatment

Collection of express, oral consent

Available for follow-up visits

Disqualifiers

Patients with neuropathic pain

History of fracture of the lower limb, surgery on the lower limb, inflammatory rheumatism of the lower limb, injury to the Achilles tendon

Patient with another painful orthopedic lesion of the legs/feet

Patient with surgically treated plantar fasciitis in the year prior to inclusion

Trial design

Design model

Single group

Treatments tested in this trial

  • Ankle Dorsiflexion Index (ADI) measurement

    Diagnostic test

    Ankle Dorsiflexion Index (ADI) measurement at D0 and W8

Treatment groups

100 Participants
are divided into 1 treatment group
Group A: Ankle Dorsiflexion Index (ADI) measurementExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Prevalence of gastrocnemius muscle retraction in patients with plantar fasciitis

retraction of the gastrocnemius muscles will be defined by an ADI of less than 13° measured by a digital inclinometer

Time frame
At Day 0

Secondary outcomes

1

correlation between ADI measurement and Manchester Oxford Foot Questionnaire (MOXFQ)

The Manchester Oxford Foot Questionnaire (MOXFQ) is used to measure the impact of foot pain on patients' quality of life. It consists of 16 questions. The raw scores of the scales are converted into a metric scale ranging from 0 to 100, where 100 indicates the maximum intensity of suffering or limitation.

Time frame
At Day 0
2

correlation between ADI measurement and pain Visual Analog Scale (VAS)

The VAS consists of a straight line where one extreme represents the total absence of pain and the other extreme, the most intense pain possible. Patients are asked to mark on this line the level of pain they feel at any given moment. Pain intensity is then measured according to the distance between the start of the scale (0) and the point where the patient placed his mark: * 0 cm (or the start of the scale): No pain * 10 cm (or the end of the scale): Maximum imaginable pain

Time frame
At Day 0
3

Evolution of Visual Analog Scale (VAS)

The VAS consists of a straight line where one extreme represents the total absence of pain and the other extreme, the most intense pain possible. Patients are asked to mark on this line the level of pain they feel at any given moment. Pain intensity is then measured according to the distance between the start of the scale (0) and the point where the patient placed his mark: - 0 cm (or the start of the scale): No pain - 10 cm (or the end of the scale): Maximum imaginable pain

Time frame
between Day 0 and Week 8
4

Evolution of Visual Analog Scale (VAS)

The VAS consists of a straight line where one extreme represents the total absence of pain and the other extreme, the most intense pain possible. Patients are asked to mark on this line the level of pain they feel at any given moment. Pain intensity is then measured according to the distance between the start of the scale (0) and the point where the patient placed his mark: - 0 cm (or the start of the scale): No pain - 10 cm (or the end of the scale): Maximum imaginable pain

Time frame
between Day 0 and Week 16

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: